966 research outputs found

    One hundred years after the discovery of insulin and glucagon:the history of tumors and hyperplasias that hypersecrete these hormones

    Get PDF
    One century ago, in 1922, Frederick G Banting, Charles H Best, James B Collip and John J R Macleod first published their experiments resulting in the isolation of a hypoglycemic factor, named insulin, from a solution extract from a dog’s pancreas. One year later, in 1923, a hyperglycemic factor named glucagon was isolated by Charles P Kimball and John R Murlin. In the following years, it could be demonstrated that pancreatic islet alpha- and beta-cell neoplasms and hyperplasias could inappropriately secrete excessive amounts of these two hormones. This review is a sequel to the discovery of insulin and glucagon and introduces the history of this fascinating group of neuroendocrine neoplasms and hyperplasias of the pancreas.</p

    Medical treatment of neuroendocrine neoplasms

    Get PDF
    Medical therapy of clinically nonfunctioning (nonsecreting) low grade (grade 1–2) neuroendocrine neoplasms consists of first-line first generation somatostatin analogs and second-line or third-line peptide receptor radiotherapy with radiolabeled beta-emitting somatostatin analogs, Everolimus, Sunitinib, and interferon-α. Second-generation somatostatin analogs like Pasireotide have no proven superiority over first-generation somatostatin analogs. Chemotherapy is usually reserved as second-line therapy in pancreatic neuroendocrine neoplasms and neuroendocrine carcinomas.</p

    Search for gamma‐ray emission from AGN with COMPTEL

    Get PDF
    The COMPTEL data (∼0.7–30 MeV) were searched for emission from AGN. Four sources have been detected so far: the quasars 3C 273, 3C 279, PKS 0528+134, and the radio galaxy Centaurus A. 3C 273 and 3C 279 were detected in CGRO observation period 3 with quite different spectral shapes. There is also evidence for 3C 273 at a weak flux level in observation period 11. The quasar PKS 0528+134 was detected above 3 MeV as part of a search for AGN already observed by EGRET. Cen A was seen up to 3 MeV by combining data from different observation periods

    COMPTEL observations of the inner galaxy

    Get PDF
    This paper presents a first global study of COMPTEL observations of the inner Galaxy in the energy range 0.75–10 MeV. Preliminary findings demonstrate COMPTEL’s capabilities for mapping the observed gamma radiation and disentangling the contributions from point sources and diffuse emission

    The interstellar oxygen-K absorption edge as observed by XMM-Newton

    Full text link
    High resolution X-ray spectra of the Reflection Grating Spectrometer (RGS) on board the XMM satellite are used to resolve the oxygen K absorption edge. By combining spectra of low and high extinction sources, the observed absorption edge can be split in the true interstellar (ISM) extinction and the instrumental absorption. The detailed ISM edge structure closely follows the edge structure of neutral oxygen as derived by theoretical R-matrix calculations. However, the position of the theoretical edge requires a wavelength shift. In addition the detailed instrumental RGS absorption edge structure is presented. All results are verified by comparing to a subset of Chandra LETG-HRC observations.Comment: LaTeX2e A&A style, 10 pages, 12 postscript figures, accepted for publication in Astronomy and Astrophysic

    Unfavorable biological behavior and treatment response of neuroendocrine ovarian metastases of midgut neuroendocrine tumors

    Get PDF
    Neuroendocrine ovarian metastases (NOM) predominantly derive from midgut neuroendocrine tumors (NETs) and develop in about 25% of women with advanced stage of this malignancy. Little is known of the growth rate and treatment response of NOM. We therefore evaluated the efficacy of different management options for patients with NOM, including peptide receptor radionuclide therapy (PRRT), somatostatin analogues (SSAs) and oophorectomy. Records were screened for patients with well-differentiated NOM of midgut origin that presented in our NET referral center between 1991 and 2022. Progression-free survival (PFS) and tumor growth rate (TGR) of ovarian and extra-ovarian metastases were determined using RECIST (response evaluation criteria in solid tumors) 1.1. In 12 available patients undergoing PRRT, NOM were associated with a shorter PFS than extra-ovarian metastases (P = 0.003). While PRRT induced a similar decrease in TGR for ovarian and extra-ovarian lesions in nine patients with available data (-2.3 vs -1.4, P &gt; 0.05), only the TGR of NOM remained positive after PRRT. In 16 patients treated with SSAs, the TGR of NOM was almost three times that of extra-ovarian lesions during treatment (2.2 vs 0.8, P = 0.011). Oophorectomy was performed in 46 of the 61 included patients and was significantly associated with a prolonged OS (115 vs 38 months, P &lt; 0.001). This association persisted after propensity score matching and correction for tumor grade and simultaneous tumor debulking. In conclusion, NOM have a higher TGR compared to extra-ovarian metastases, resulting in a shorter PFS after PRRT. Bilateral salpingo-oophorectomy should be considered for postmenopausal women with NOM undergoing surgery for metastatic midgut NETs.</p
    corecore